John Magnani

FAQ About John Magnani

• What is John Magnani's address?

  John Magnani is located at
  12819 Doe Lane, Gaithersburg, United States

• What is John Magnani's job title?

  John Magnani is a
  • Received a Ph.D. from Princeton University on a full academic scholarship and a Teaching Assistantship • Research at the National Institutes of Health (NIH) for ten years ending with a permanent position (tenure) as a Research Chemist • Developed fundamental methods for determining structures of ligands for carbohydrate-binding proteins resulting in the description of cancer-associated carbohydrate antigens. • Discovered the FDA-approved CA19-9 assay for pancreatic cancer now in routine clinical use for over 20 years. Invited to publish a “Reflections” article by the journal Clinical Chemistry on my personal account of the discovery of the FDA-approved CA19-9 pancreatic cancer assay, [ref. 93, Clin Chem. 59(1), 22-31 (2013)]. • Discovered the structure of sialyl Lea and its function as a ligand for E-selectin and first to determine the trisaccharide domain common to both sialyl Lea and sialyl Lex as the epitope for E-selectin. • Developed a rational design approach to create a new class of potent drugs known as glycomimetics that are based on the bioactive conformations of functional carbohydrates. • Using this unique platform, designed, and developed four drugs advanced toward clinical trials. Rivipansel for sickle cell disease, Uproleselan which just finished a Phase 3 clinical study to treat patients with acute myelogenous leukemia (AML) GMI-1359 in Phase 1 studies to treat breast cancer and GMI-1687 currently awarded an IND by the FDA for early treatment of vaso-occlusive crisis in sickle cell disease. • Founded or Co/founded 3 biotech companies, BioCarb, Inc., GlycoTech, Inc., and GlycoMimetics, Inc. • Succeeded in advancing GlycoMimetics Inc to a public company (IPO) on the NASDAQ stock exchange and ringing the closing bell. • Chosen as one of two Glycobiologists representing the United States by Canada to participate in the original meeting in Ottawa to evaluate and approve the creation of GlycoNet, a pan-Canadian network to translate Glycomics to treat unmet medical needs. • Authored over 100 publications in peer-reviewed journals. • An Inventor on over 100 issued worldwide patents. • Received the President’s Innovator Award from the Society for Glycobiology in 2015. • Received the Horton Award from the American Chemical Society in 2020. • Elected to the Executive Committee of CARB in the American Chemical Society in 2022. Glycomimetics

• What industry does John Magnani currently work in?

  John Magnani currently works in the
  Glycomimetics

• What is John Magnani's area of expertise?

  John Magnani specializes in
  • Received a Ph.D. from Princeton University on a full academic scholarship and a Teaching Assistantship • Research at the National Institutes of Health (NIH) for ten years ending with a permanent position (tenure) as a Research Chemist • Developed fundamental methods for determining structures of ligands for carbohydrate-binding proteins resulting in the description of cancer-associated carbohydrate antigens. • Discovered the FDA-approved CA19-9 assay for pancreatic cancer now in routine clinical use for over 20 years. Invited to publish a “Reflections” article by the journal Clinical Chemistry on my personal account of the discovery of the FDA-approved CA19-9 pancreatic cancer assay, [ref. 93, Clin Chem. 59(1), 22-31 (2013)]. • Discovered the structure of sialyl Lea and its function as a ligand for E-selectin and first to determine the trisaccharide domain common to both sialyl Lea and sialyl Lex as the epitope for E-selectin. • Developed a rational design approach to create a new class of potent drugs known as glycomimetics that are based on the bioactive conformations of functional carbohydrates. • Using this unique platform, designed, and developed four drugs advanced toward clinical trials. Rivipansel for sickle cell disease, Uproleselan which just finished a Phase 3 clinical study to treat patients with acute myelogenous leukemia (AML) GMI-1359 in Phase 1 studies to treat breast cancer and GMI-1687 currently awarded an IND by the FDA for early treatment of vaso-occlusive crisis in sickle cell disease. • Founded or Co/founded 3 biotech companies, BioCarb, Inc., GlycoTech, Inc., and GlycoMimetics, Inc. • Succeeded in advancing GlycoMimetics Inc to a public company (IPO) on the NASDAQ stock exchange and ringing the closing bell. • Chosen as one of two Glycobiologists representing the United States by Canada to participate in the original meeting in Ottawa to evaluate and approve the creation of GlycoNet, a pan-Canadian network to translate Glycomics to treat unmet medical needs. • Authored over 100 publications in peer-reviewed journals. • An Inventor on over 100 issued worldwide patents. • Received the President’s Innovator Award from the Society for Glycobiology in 2015. • Received the Horton Award from the American Chemical Society in 2020. • Elected to the Executive Committee of CARB in the American Chemical Society in 2022.

• Which languages does John Magnani speak? 

  John Magnani speaks the following languages:
  No languages available.

• Which industries has John Magnani previously worked in?   

  John Magnani has prior experience in the following industries:
  Glycomimetics , National Institutes Of Health

• What is John Magnani’s work experience?  

  John Magnani has the following professional experience:
  Glycomimetics , Glycotech , National Institutes Of Health .

• How can I find John Magnani on LinkedIn?  

  You can view John Magnani’s
  LinkedIn profile at LinkedIn URL.

• What are John Magnani’s work email addresses?  

  John Magnani’s work email addresses are
  [email protected] .

• What company does John Magnani work for?  

  John Magnani works at
  Glycomimetics